New hope for rare blood disorder: experimental drug TGD001 enters human trials

This early-phase trial tests a new drug called TGD001 in about 70 adults with acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) or related blood clotting conditions. The main goal is to check the drug's safety and how the body processes it, while also looking at whether it helps resolve clotting episodes faster. Participants receive the drug openly (no placebo) and are monitored closely for side effects and recovery.